Search Results - "MERLINI, G"

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis by Comenzo, R L, Reece, D, Palladini, G, Seldin, D, Sanchorawala, V, Landau, H, Falk, R, Wells, K, Solomon, A, Wechalekar, A, Zonder, J, Dispenzieri, A, Gertz, M, Streicher, H, Skinner, M, Kyle, R A, Merlini, G

“…This manuscript summarizes the recommendations that emerged from the first Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis (AL), a…”
Get full text

Light chain amyloidosis: the heart of the problem by Merlini, Giampaolo, Palladini, Giovanni

Get full text

AL Amyloidosis by Merlini, G

Get full text

AA amyloidosis: basic knowledge, unmet needs and future treatments by Obici, Laura, Merlini, Giampaolo

“…Systemic AA amyloidosis is a long-term complication of several chronic inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis,…”
Get full text

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies by Merlini, G, Westermark, P

“… Knowledge about the systemic amyloidoses has increased considerably during the last few years. This group of diseases is characterized by great biochemical…”
Get full text

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients by Palladini, G, Milani, P, Foli, A, Vidus Rosin, M, Basset, M, Lavatelli, F, Nuvolone, M, Obici, L, Perlini, S, Merlini, G

“…Oral melphalan and dexamethasone (MDex) is a standard treatment for patients with AL amyloidosis who are not eligible for stem cell transplantation at many…”
Get full text

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis by Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L

“…Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis,…”
Get full text

Amyloidosis: is a cure possible? by Merlini, G., Palladini, G.

Get full text

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial by Brannagan, T. H., Wang, A. K., Coelho, T., Waddington Cruz, M., Polydefkis, M. J., Dyck, P. J., Plante‐Bordeneuve, V., Berk, J. L., Barroso, F., Merlini, G., Conceição, I., Hughes, S. G., Kwoh, J., Jung, S. W., Guthrie, S., Pollock, M., Benson, M. D., Gertz, M., Drachman, Brian, Gorevic, Peter, Heitner, Stephen, Scheinberg, Morton, Schmidt, Hartmut, Whelan, Carol, Adams, David, Campistol Plana, Josep Maria, Gamez, Josep, Gane, Edward, Kristen, Arnt, Obici, Laura, Salvi, Fabrizio, Souza Bulle Oliveira, Acary, Vita, Giuseppe

“…Background and purpose Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition…”
Get full text

International uniform response criteria for multiple myeloma by DURIE, B. G. M, HAROUSSEAU, J.-L, LUDWIG, H, GAHRTON, G, BEKSAC, M, CROWLEY, J, BELCH, A, BOCCADARO, M, TURESSON, I, JOSHUA, D, VESOLE, D, KYLE, R, MIGUEL, J. S, ALEXANIAN, R, TRICOT, G, ATTAL, M, MERLINI, G, POWLES, R, RICHARDSON, P, SHIMIZU, K, TOSI, P, MORGAN, G, RAJKUMAR, S. V, BLADE, J, BARLOGIE, B, ANDERSON, K, GERTZ, M, DIMOPOULOS, M, WESTIN, J, SONNEVELD, P

“…New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow…”
Get full text

Management of treatment-emergent peripheral neuropathy in multiple myeloma by Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, Sonneveld, P

“…Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects…”
Get full text

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel by Caers, J, Paiva, B, Zamagni, E, Leleu, X, Bladé, J, Kristinsson, S Y, Touzeau, C, Abildgaard, N, Terpos, E, Heusschen, R, Ocio, E, Delforge, M, Sezer, O, Beksac, M, Ludwig, H, Merlini, G, Moreau, P, Zweegman, S, Engelhardt, M, Rosiñol, L

“…Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary…”
Get full text

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma by da Silva Filho, M I, Försti, A, Weinhold, N, Meziane, I, Campo, C, Huhn, S, Nickel, J, Hoffmann, P, Nöthen, M M, Jöckel, K-H, Landi, S, Mitchell, J S, Johnson, D, Morgan, G J, Houlston, R, Goldschmidt, H, Jauch, A, Milani, P, Merlini, G, Rowcieno, D, Hawkins, P, Hegenbart, U, Palladini, G, Wechalekar, A, Schönland, S O, Hemminki, K

“…Immunoglobulin light chain (AL) amyloidosis is characterized by tissue deposition of amyloid fibers derived from immunoglobulin light chain. AL amyloidosis and…”
Get full text

Bortezomib in the treatment of AL amyloidosis: targeted therapy? by Sitia, Roberto, Palladini, Giovanni, Merlini, Giampaolo

Get full text

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) by Palladini, Giovanni, Perfetti, Vittorio, Perlini, Stefano, Obici, Laura, Lavatelli, Francesca, Caccialanza, Riccardo, Invernizzi, Rosangela, Comotti, Benedetto, Merlini, Giampaolo

“…Based on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of…”
Get full text

A revised international prognostic score system for Waldenström’s macroglobulinemia by Gavriatopoulou, M., Kastritis, E., Morel, P., Duhamel, A., Kyrtsonis, M.C., Durot, E., Symeonidis, A., Laribi, K., Hatjiharisi, E., Ysebaert, L., Vassou, A., Giannakoulas, N., Merlini, G., Repousis, P., Varettoni, M., Michalis, E., Hivert, B., Michalis, M., Leblond, V., Dimopoulos, M.A.C.

Get full text

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES by Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.

Get full text

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK by Kastritis, E., Palladini, G., Dimopoulos, M. A., Jaccard, A., Merlini, G., Theodorakakou, F., Fotiou, D., Minnema, M. C., Wechalekar, A., Gkolfinopoulos, S., Manousou, K., Sonneveld, P., Schönland, S.

Get full text

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE by Jaccard, A., Bridoux, F., Roeloffzen, W., Minnema, M. C., Bergantim, R., Hájek, R., João, C., Cibeira, M. T., Palladini, G., Schönland, S., Merlini, G., Milani, P., Dimopoulos, M. A., Ravichandran, S., Hegenbart, U., Agis, H., Gros, B., Asra, A., Dergarabetian, E., Magarotto, V., Leonidakis, A., Cheliotis, G., Sonneveld, P., Wechalekar, A., Kastritis, E.

Get full text

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects by Dubrey, S.W., Reece, D.E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J.-P., Vescio, R.A., Bladé, J., Heffner, L.T., Hassoun, H., Liu, X., Enny, C., Ramaswami, P., Elsayed, Y., Van De Velde, H., Mortimer, S., Cakana, A., Comenzo, R.L.

“…Background: Bortezomib is approved for the treatment of multiple myeloma and a role has been suggested in the treatment of systemic AL amyloidosis (AL)…”
Get full text